cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, 2 trial Cagrilintide is an amylin analogue

RGN-259 treatment promoted rapid healing of corneal epithelial defects, improved Mackie classification disease stage, and produced significant improvements in ocular discomfort, foreign body sensation, and dryness, with no significant adverse effects

Over the past 20 years, we have been focusing on Preparation Technology, insisting on Innovation Development, and exploring the transformation of Pharmaceutical Technology

This supplement is not intended to diagnose, treat, cure, or prevent any disease

P6 and P7 had exclusively small bowel perforations

Dihexa was designed to be more potent, more stable, and orally bioavailable